<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825496</url>
  </required_header>
  <id_info>
    <org_study_id>ssCART-19</org_study_id>
    <nct_id>NCT04825496</nct_id>
  </id_info>
  <brief_title>Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine&#xD;
      the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed&#xD;
      or refractory acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine&#xD;
      the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed&#xD;
      or refractory acute lymphoblastic leukemia.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      Determine the safety and tolerability of ssCART-19 cells in patients with refractory or&#xD;
      relapsed acute lymphoblastic leukemia.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Observe the anti-tumor response of ssCART-19 cells to refractory or relapsed acute&#xD;
           lymphoblastic leukemia.&#xD;
&#xD;
             -  Overall remission rate (ORR) assessment during the 3 months after ssCART-19&#xD;
                administration，ORR includes CR and CRi&#xD;
&#xD;
             -  Duration of response (DOR)&#xD;
&#xD;
             -  Progression-free survival (PFS)&#xD;
&#xD;
             -  Overall survival (OS)&#xD;
&#xD;
        2. To characterize the in vivo cellular pharmacokinetic (PK) profile of ssCART-19 cells.&#xD;
&#xD;
        3. To characterize the pharmacodynamic (PD) profile of ssCART-19 cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Determine the safety and tolerability of ssCART-19 in patients with refractory or relapsed acute lymphoblastic leukemia.&#xD;
Safety measures include adverse events as assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Remission Rate (ORR), which includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy of ssCART-19 as measured by ORR during the 3 months after ssCART-19 infusion, which includes CR and CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Statistical parameter:Duration of remission (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Statistical parameter:Progression-free Survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Statistical parameter:Overall survival (OS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cellular pharmacokinetic (PK) profile of ssCART-19 cells</measure>
    <time_frame>24 months</time_frame>
    <description>Number of DNA copies of ssCART-19 cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-drug antibody</measure>
    <time_frame>24 months</time_frame>
    <description>Detect titer of anti-drug antibody (ADA)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Relapsed or Refractory Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>ssCART-19 Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Intravenous injection.&#xD;
Lymphodepletion conditioning:&#xD;
Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.&#xD;
A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ssCART-19 Cells</intervention_name>
    <description>Split-Dose of ssCART-19 cells will be infused, and classic &quot;3+3&quot; dose escalation will be applied.</description>
    <arm_group_label>ssCART-19 Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine is used for lymphodepletion.</description>
    <arm_group_label>ssCART-19 Cells</arm_group_label>
    <other_name>FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is used for lymphodepletion.</description>
    <arm_group_label>ssCART-19 Cells</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed or refractory acute lymphoblastic leukemia (ALL):(1)Any Relaps after first&#xD;
             remission OR (2)Any BM relapse after allogeneic SCT and must be ≥ 3 months from SCT at&#xD;
             the time of ssCART-19 infusion OR (3)failed to reach CR after 2 cycles of induction&#xD;
             chemotherapy regimen OR (4)Patients with Ph+ ALL are eligible if they are intolerant&#xD;
             to or have failed two lines of TKI therapy, or if TKI therapy is contraindicated&#xD;
&#xD;
          2. CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow&#xD;
             cytometry&#xD;
&#xD;
          3. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment&#xD;
&#xD;
          4. Adequate organ function defined as:(1)left ventricular ejection fraction ≥ 50% by&#xD;
             echocardiogram；(2)creatinine ≤ 1.6mg/dl；(3)ALT and AST≤3 times the ULN for age, total&#xD;
             bilirubin ≤ 2.0mg/dl；(4)Must have a minimum level of pulmonary reserve defined as ≤&#xD;
             Grade 1 dyspnea and pulse oxygenation &gt; 91% on room air&#xD;
&#xD;
          5. Informed consent is signed by the subject&#xD;
&#xD;
          6. Age 18 to 65&#xD;
&#xD;
          7. Fertility of men, to ensure that sexual partners can effectively contraception; Women&#xD;
             with fertility use effective contraceptive measures and agree to use contraceptive&#xD;
             measures throughout the study period&#xD;
&#xD;
          8. Qualified T cell amplification&#xD;
&#xD;
          9. Eastern cooperative oncology group (ECOG) performance status of 0 to 1&#xD;
&#xD;
         10. Vascular conditions for apheresis&#xD;
&#xD;
         11. The estimated survival time is more than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated extra-medullary disease relapse&#xD;
&#xD;
          2. Combined with other malignant tumors&#xD;
&#xD;
          3. Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other antiCD19&#xD;
             therapy&#xD;
&#xD;
          4. Has had immunosuppressants or hormones within 2 weeks before signing informed consent,&#xD;
             or plan to use immunosuppressants or hormones after signing informed consent&#xD;
&#xD;
          5. Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B&#xD;
             e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core&#xD;
             antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of&#xD;
             detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody&#xD;
             (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of&#xD;
             detection&#xD;
&#xD;
          6. Has uncontrolled bacteria, fungi, viruses, mycoplasma or other types of infections&#xD;
&#xD;
          7. Infected with HIV, syphilis or COVID-19&#xD;
&#xD;
          8. Has a history of severe immediate hypersensitivity to aminoglycosides&#xD;
&#xD;
          9. Has past or present CNS diseases, such as epilepsy, cerebrovascular&#xD;
             ischemia/hemorrhage, dementia, cerebellar diseases or any CNS-related autoimmune&#xD;
             diseases&#xD;
&#xD;
         10. Has undergone cardiac angioplasty or stent implantation within 12 months before&#xD;
             signing informed consent, or having a history of myocardial infarction, unstable&#xD;
             angina pectoris or other clinically significant heart diseases&#xD;
&#xD;
         11. With primary immunodeficiency&#xD;
&#xD;
         12. Has had severe immediate hypersensitivity reaction to any drug to be used in this&#xD;
             study&#xD;
&#xD;
         13. Has had treat with live vaccine within 6 weeks prior to screening&#xD;
&#xD;
         14. Pregnant or lactating women&#xD;
&#xD;
         15. Has active autoimmune diseases&#xD;
&#xD;
         16. Has active acute or chronic graft-versus-host disease (GVHD) before signing informed&#xD;
             consent&#xD;
&#xD;
         17. Patient has an investigational medicinal product within 3 months before signing&#xD;
             informed consent&#xD;
&#xD;
         18. Patients with other conditions making the patients unsuitable for receiving cell&#xD;
             therapy as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Lou, Dr.</last_name>
    <phone>18721281671</phone>
    <email>xiaoyan.lou@unicar-therapy.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liqing Kang, Dr.</last_name>
    <phone>13162512992</phone>
    <email>liqing.kang@unicar-therapy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201210</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Lou, Dr.</last_name>
      <phone>18721281671</phone>
      <email>xiaoyan.lou@unicar-therapy.com</email>
    </contact>
    <contact_backup>
      <last_name>Liqing Kang, Dr.</last_name>
      <phone>13162512992</phone>
      <email>liqing.kang@unicar-therapy.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

